{
  "docId": "019de076-4f8b-70c9-adf8-0b3abb8c1303",
  "docSlug": "1af2d4156bf2490b3ac2801b5487abdf",
  "documentTitle": "Larimar Therapeutics | Investor Presentation Deck | 44 slides",
  "authorId": "larimar-therapeutics",
  "authorName": "Larimar Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 18,
  "pageCount": 44,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 1,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-4f8b-70c9-adf8-0b3abb8c1303/18",
  "deckHref": "/decks/019de076-4f8b-70c9-adf8-0b3abb8c1303",
  "deckJsonHref": "/decks/019de076-4f8b-70c9-adf8-0b3abb8c1303.json",
  "deckAnchorHref": "/decks/019de076-4f8b-70c9-adf8-0b3abb8c1303#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.75,
        "x": 0.18,
        "y": 0.2
      },
      "kind": "list",
      "text": "Generally well tolerated in Phase 1 and Phase 2 cohort 1; Dose-dependent increases in FXN levels in all evaluated tissues in Phase 1; Increases in FXN from baseline compared to placebo in all evaluated tissues (skin and buccal cells) in Phase 2 cohort 1",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "502bbdaf-9dac-4ae5-b5f1-03e0cd8e317f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.75,
        "x": 0.18,
        "y": 0.43
      },
      "kind": "list",
      "text": "Phase 2 dose exploration trial of nomlabofusp (CTI-1601) in FA cleared to proceed to 50 mg cohort; Open label extension trial with 25 mg daily dosing cleared for initiation; Beginning preparations to expand nomlabofusp (CTI-1601) clinical program to ex-U.S. geographies",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5afba554-6bc5-41f6-bd1d-76f7f4dfc0fa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.75,
        "x": 0.18,
        "y": 0.65
      },
      "kind": "list",
      "text": "Q4 2023: Completed full enrollment (15 participants) and dosing of the 50 mg cohort in Phase 2 dose exploration trial; Q1 2024: Top-line Phase 2 data from 50 mg and 25 mg cohorts; Q1 2024: Initiation of open-label extension (OLE) trial; Q4 2024: Interim data from OLE trial",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "08184490-6d30-4be1-929f-e54a686cdca1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.94,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "Top-line Phase 2 50 mg & 25 mg Cohort Data & OLE Initiation in Q1 2024",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6ad8bbe3-9477-41ac-b53f-8b8f703c03a4",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 44,
      "from": 4,
      "beatId": "800ed350-717e-4cf5-a054-3d6626879633",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "Multiple pages showcase clinical trial progress and data",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 18,
      "from": 15,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "b4351c10-987b-4a01-94eb-9553dbddf999",
      "evidence": "Pages 15-18 discuss the clinical development plan and upcoming milestones",
      "position": 2,
      "objective": "What are the near-term milestones?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}